Altered expression of fibronectin and collagens I and IV in multiple myeloma and monoclonal gammopathy of undetermined significance

Journal of Histochemistry and Cytochemistry

Volumn 57, Issue 3, 2009, Pages 239-247

  Tancred, Tara M ^a   Belch, Andrew R ^a   Reiman, Tony ^a   Pilarski, Linda M ^a   Kirshner, Julia ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Bone marrow microenvironment; Collagen I; Collagen IV; Extracellular matrix; Fibronectin; Immunohistochemistry; Laminin; Monoclonal gammopathy of undetermined significance; Multiple myeloma

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 4; FIBRONECTIN; LAMININ; SCLEROPROTEIN;

ADULT; AGED; ARTICLE; BONE MARROW; CELL INTERACTION; CELL ISOLATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MALE; MICROENVIRONMENT; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PLASMACYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; BIOSYNTHESIS; BONE; COMPARATIVE STUDY; EXTRACELLULAR MATRIX; METABOLISM; MIDDLE AGED; PARAPROTEINEMIA; PLASMA CELL;

ADULT; AGED; AGED, 80 AND OVER; BONE AND BONES; BONE MARROW; COLLAGEN TYPE I; COLLAGEN TYPE IV; EXTRACELLULAR MATRIX; FEMALE; FIBRONECTINS; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PARAPROTEINEMIAS; PLASMA CELLS;

EID: 62649169258     PISSN: 00221554     EISSN: None     Source Type: Journal    
DOI: 10.1369/jhc.2008.952200     Document Type: Article

References (52)

1. Adams GB, Scadden DT (2006) The hematopoietic stem cell in its place. Nat Immunol 7:333-337
2. Barcellos-Hoff MH, Ravani SA (2000) Irradiated mammary gland stroma promotes the expression of tumorigenic potential by un-irradiated epithelial cells. Cancer Res 60:1254-1260
3. Bataille R, Manolagas SC, Berenson JR (1997) Pathogenesis and management of bone lesions in multiple myeloma. Hematol Oncol Clin North Am 11:349-361
4. Billadeau D, Van Ness B, Kimlinger T, Kyle RA, Therneau TM, Greipp PR, Witzig TE (1996) Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma. Blood 88:289-296
5. Bouterfa H, Darlapp AR, Klein E, Pietsch T, Roosen K, Tonn JC (1999) Expression of different extracellular matrix components in human brain tumor and melanoma cells in respect to variant culture conditions. J Neurooncol 44:23-33
6. Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC, Martin RP, et al. (2003) Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425:841-846
7. Dalton WS, Hazlehurst L, Shain K, Landowski T, Alsina M (2004) Targeting the bone marrow microenvironment in hematologic malignancies. Semin Hematol 41:1-5
8. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS (1999) Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93:1658-1667
9. Donnenberg VS, Donnenberg AD (2005) Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol 45:872-877
10. Eleutherakis-Papaiakovou V, Bamias A, Gika D, Simeonidis A, Pouli A, Anagnostopoulos A, Michali E, et al. (2007) Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma 48:337-341
11. Fuks Z, Vlodavsky I, Andreeff M, Mcloughlin M, Haimovitz-Friedman A (1992) Effects of extracellular matrix on the response of endothelial cells to radiation in vitro. Eur J Cancer 28A:725-731
12. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, Boccadoro M, et al. (2005) International staging system for multiple myeloma. J Clin Oncol 23:3412-3420
13. Gu YC, Kortesmaa J, Tryggvason K, Persson J, Ekblom P, Jacobsen SE, Ekblom M (2003) Laminin isoform-specific promotion of adhesion and migration of human bone marrow progenitor cells. Blood 101:877-885
14. Gutierrez NC, Camps J, Hernandez JM, Garcia JL, Prat E, Gonzalez MB, Miro R, et al. (2003) Multicolor fluorescence in situ hybridization studies in multiple myeloma and monoclonal gammopathy of undetermined significance. Hematol J 4:67-70
15. Haylock DN, Williams B, Johnston HM, Liu MC, Rutherford KE, Whitty GA, Simmons PJ, et al. (2007) Hemopoietic stem cells with higher hemopoietic potential reside at the bone marrow endosteum. Stem Cells 25:1062-1069
16. Hazlehurst LA, Argilagos RF, Emmons M, Boulware D, Beam CA, Sullivan DM, Dalton WS (2006) Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells. Cancer Res 66:2338-2345
17. Hazlehurst LA, Dalton WS (2001) Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies. Cancer Metastasis Rev 20:43-50
18. Hurley RW, Mccarthy JB, Verfaillie CM (1995) Direct adhesion to bone marrow stroma via fibronectin receptors inhibits hematopoietic progenitor proliferation. J Clin Invest 96:511-519
19. Kibler C, Schermutzki F, Waller HD, Timpl R, Muller CA, Klein G (1998) Adhesive interactions of human multiple myeloma cell lines with different extracellular matrix molecules. Cell Adhes Commun 5:307-323
20. Kiel MJ, Yilmaz OH, Iwashita T, Yilmaz OH, Terhorst C, Morrison SJ (2005) SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 121:1109-1121
21. Kirshner J, Thulien KJ, Martin LD, Debes Marun C, Reiman T, Belch AR, Pilarski LM (2008) A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma. Blood 112:2935-2945
22. Kollet O, Dar A, Shivtiel S, Kalinkovich A, Lapid K, Sztainberg Y, Tesio M, et al. (2006) Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat Med 12:657-664
23. Kuehl WM, Bergsagel PL (2002) Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2:175-187
24. Kyle RA, Rajkumar SV (2007) Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression. Br J Haematol 139:730-743
25. Landgren O, Gridley G, Turesson I, Caporaso NE, Goldin LR, Baris D, Fears TR, et al. (2006) Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 107:904-906
26. Li AH, Forestier E, Rosenquist R, Roos G (2002) Minimal residual disease quantification in childhood acute lymphoblastic leukemia by real-time polymerase chain reaction using the SYBR green dye. Exp Hematol 30:1170-1177
27. Lord BI, Testa NG, Hendry JH (1975) The relative spatial distributions of CFUs and CFUc in the normal mouse femur. Blood 46:65-72
28. Ludwig H, Pohl G, Osterborg A (2004) Anemia in multiple myeloma. Clin Adv Hematol Oncol 2:233-241
29. Lust JA, Donovan KA (1998) Biology of the transition of monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma. Cancer Control 5:209-217
30. MaffiniMV, Soto AM, Calabro JM, Ucci AA, Sonnenschein C (2004) The stroma as a crucial target in rat mammary gland carcinogenesis. J Cell Sci 117:1495-1502
31. Martin-Jimenez P, Garcia-Sanz R, Balanzategui A, Alcoceba M, Ocio E, Sanchez ML, Gonzalez M, et al. (2007) Molecular characterization of heavy chain immunoglobulin gene rearrangements in Waldenstrom's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. Haematologica 92: 635-642
32. Matsunaga T, Fukai F, Miura S, Nakane Y, Owaki T, Kodama H, Tanaka M, et al. (2008) Combination therapy of an anticancer drug with the FNIII14 peptide of fibronectin effectively overcomes cell adhesion-mediated drug resistance of acute myelogenous leukemia. Leukemia 22:353-360
33. Nefedova Y, Landowski TH, Dalton WS (2003) Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 17:1175-1182
34. Nilsson SK, Debatis ME, Dooner MS, Madri JA, Quesenberry PJ, Becker PS (1998) Immunofluorescence characterization of key extracellular matrix proteins in murine bone marrow in situ. J Histochem Cytochem 46:371-377
35. Oken MM, Pomeroy C,Weisdorf D, Bennett JM (1996) Prophylactic antibiotics for the prevention of early infection in multiple myeloma. Am J Med 100:624-628
36. Pilarski LM, Baigorri E, Mant MJ, Pilarski PM, Adamson P, Zola H, Belch AR (2008) Multiple myeloma includes phenotypically defined subsets of clonotypic CD201 B cells that persist during treatment with rituximab. Oncology 2:275-287
37. Pilarski LM, Hipperson G, Seeberger K, Pruski E, Coupland RW, Belch AR (2000) Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood 95:1056-1065
38. Pilarski LM, Seeberger K, Coupland RW, Eshpeter A, Keats JJ, Taylor BJ, Belch AR (2002) Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice. Exp Hematol 30:221-228
39. Reiman T, Seeberger K, Taylor BJ, Szczepek AJ, Hanson J, Mant MJ, Coupland RW, et al. (2001) Persistent preswitch clonotypic myeloma cells correlate with decreased survival: evidence for isotype switching within the myeloma clone. Blood 98:2791-2799
40. Reincke U, Hsieh P, Mauch P, Hellman S, Chen LB (1982) Cell types associated with fibronectin in long-term mouse bone marrow cultures. J Histochem Cytochem 30:235-244
41. Schmidmaier R, Baumann P, Simsek M, Dayyani F, Emmerich B, Meinhardt G (2004) The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase. Blood 104:1825-1832
42. Schmidmaier R, Morsdorf K, Baumann P, Emmerich B, Meinhardt G (2006) Evidence for cell adhesion-mediated drug resistance of multiple myeloma cells in vivo. Int J Biol Markers 21:218-222
43. Sugiyama T, Kohara H, Noda M, Nagasawa T (2006) Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 25:977-988
44. Thulien KJ, Reiman T, Belch AR, Booth J, Pilarski LM (2006) Quantitative detection using SYBR green of residual disease in myeloma patients treated with Revlimid or Velcade. Blood 108:5102
45. Tucci A, Bonadonna S, Cattaneo C, Ungari M, Giustina A, Guiseppe R (2003) Transformation of a MGUS to overt multiple myeloma: the possible role of a pituitary macroadenoma secreting high levels of insulin-like growth factor 1 (IGF-1). Leuk Lymphoma 44:543-545
46. Vincent T, Mechti N (2005) Extracellular matrix in bone marrow can mediate drug resistance in myeloma. Leuk Lymphoma 46: 803-811
47. WesthoffMA, Zhou S, Bachem MG, Debatin KM, Fulda S (2008) Identification of a novel switch in the dominant forms of cell adhesionmediated drug resistance in glioblastoma cells. Oncogene 27: 5169-5181
48. Wilson A, Trumpp A (2006) Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol 6:93-106
49. Yanamandra N, Colaco NM, Parquet NA, Buzzeo RW, Boulware D, Wright G, Perez LE, et al. (2006) Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia. Clin Cancer Res 12:591-599
50. Zhang J, Niu C, Ye L, Huang H, He X, Tong WG, Ross J, et al. (2003) Identification of the haematopoietic stem cell niche and control of the niche size. Nature 425:836-841
51. Zojer N, Ludwig H, Fiegl M, Stevenson FK, Sahota SS (2003) Patterns of somatic mutations in VH genes reveal pathways of clonal transformation fromMGUS tomultiplemyeloma. Blood 101:4137-4139
52. Zuckerman KS, Wicha MS (1983) Extracellular matrix production by the adherent cells of long-term murine bone marrow cultures. Blood 61:540-547